Search the Newsreel

Ermenegildo Zegna N.V. Revenue Breakdown – BX:ZGN

Ermenegildo Zegna N.V. (BX:ZGN) generated 1.78 billion CHF in the last year, with its top segment, Zegna, contributing 1.19 billion CHF. The United States was the leading regional contributor, accounting for 431.65 million CHF. This data provides a breakdown of the company's revenue performance …

INVESTIGATION NOTICE: Hagens Berman Encourages Former HanesBrands Investors Who Received Gildan (NYSE: GIL) Shares in Connection with Gildan's Acquisition of HanesBrands in December 2025 to Contact the Firm

Hagens Berman has initiated an investigation into Gildan Activewear (NYSE: GIL) following a critical report by Jehoshaphat Research, which alleges improper channel stuffing and revenue recognition practices. The report, published on June 16, caused Gildan's stock to tumble over 18%, wiping out $2.15 billion …

Gilead Sciences stock may move 4.3% on August earnings report By Investing.com

Gilead Sciences Inc. (NYSE:GILD) stock is projected to move 4.3% following its upcoming August 4 earnings report, according to options data compiled by Bloomberg. Historical data indicates that the stock's actual movement has sometimes exceeded options traders' anticipation, with past earnings reports showing both …

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Wall Street expects a year-over-year decline in earnings on higher revenues when Gilead Sciences (GILD) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term …

Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating

Barclays has adjusted its price target for Gilead Sciences (GILD) to $145, down from the previous $155, while reiterating an "Equalweight" rating on the stock. This update reflects a revised valuation perspective from the firm. The article also provides a brief company profile, detailing …

Gildan Activewear, Inc. $GIL Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company significantly increased its stake in Gildan Activewear, Inc. by 15.7%, now holding 6.7 million shares valued at $373.1 million. This move highlights continued institutional interest, with collective institutional ownership reaching 82.83%. Analysts maintain a "Moderate Buy" rating for Gildan …

Gilead Sciences Inc (GILD) Financial Health: Profitability & Balance Sheet Analysis

Gilead Sciences Inc (GILD) has a strong financial health score of 8.91, ranking 29th out of 155 in the Pharmaceuticals industry, indicating stable financial status and high operating efficiency. The company reported a quarterly revenue of $6.96 billion, marking a 4.39% year-over-year increase, and …

Gildan Activewear Inc. (TSE:GIL) Receives Average Rating of "Moderate Buy" from Analysts

Gildan Activewear Inc. (TSE:GIL) has received a "Moderate Buy" consensus rating from analysts, with three out of five recommending a buy and two a

ZGN|Ermenegildo Zegna NV|Price:14.940|Chg%:-0.030

The article provides a detailed overview of Ermenegildo Zegna NV (ZGN) on TradingKey, including its current stock price and key financial metrics like market cap and P/E ratio. It explains how TradingKey generates its comprehensive stock score based on various dimensions such as financial …

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

AstraZeneca's push for "Chinese speed" and ambitious 2030 sales goals are intensifying scrutiny on the pharmaceutical and biotech sectors. This article highlights Krystal Biotech, TG Therapeutics, and Gilead Sciences as examples of companies whose trajectories are particularly exposed to these industry-wide shifts. It details …

FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It

Quick Read FBT's equal-weight design beat IBB by 35 percentage points over five years, returning 47% versus IBB's 13% despite carrying a higher expense ratio. IBB puts nearly 30% into four mega-caps (Vertex, Amgen, Gilead, and Regeneron), making it behave more like a defensive …

Ermenegildo Zegna publishes corporate presentation outlining brand strategy and integrated supply chain plan

Ermenegildo Zegna has released a corporate presentation detailing its brand strategy, which focuses on three core brands: Zegna, Thom Browne, and Tom Ford Fashion, supported by a vertically integrated supply chain. The company is adopting a "One Brand" approach for Zegna, discontinuing previous lines, …

Gildan Activewear: Execution Is The Name Of The Game (NYSE:GIL)

חדשות למשקיעי Gildan: אם ספגתם הפסדים ב- Gildan Activewear Inc. (NYSE: GIL), אתם מוזמנים ליצור קשר עם משרד רוזן עורכי דין בנוגע לזכויותיכם

ניו יורק, July 27, 2026 (GLOBE NEWSWIRE) -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, ממשיך לחקור תביעות ניירות ערך פוטנציאליות מטעם בעלי המניות של Gildan Activewear Inc. (NYSE: GIL) בעקבות טענות כי Gildan Activewear פרסמה …

Gilead (GILD) Wins Key Europe Backing For Trodelvy In Triple Negative Breast Cancer

Gilead Sciences received a positive opinion from the European Medicines Agency’s CHMP for Trodelvy combined with Keytruda to treat PD-L1 positive metastatic triple-negative breast cancer. This recommendation is based on strong Phase 3 data showing reduced disease progression or death. The European Commission's subsequent …

Bronstein, Gewirtz & Grossman, LLC Encourages Gildan Activewear Inc. (GIL) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gildan Activewear Inc. (NYSE: GIL) following a report alleging channel stuffing and financial engineering. The law firm encourages Gildan investors to inquire about the securities investigation, offering assistance on a …

What Ermenegildo Zegna (ZGN)'s Stronger Q2 2026 Revenue Means For Shareholders

Ermenegildo Zegna N.V. reported stronger unaudited revenues for Q2 and H1 2026, indicating commercial traction for its luxury brands. This revenue growth supports the company's goal of building a global luxury platform, despite ongoing risks like softness in Greater China and Thom Browne wholesale …

Gilead Sciences (GILD) Gets a Hold from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD) with a price target of $120.00. Goldman Sachs also issued a Hold rating, while BMO Capital assigned a Buy rating. Gilead reported Q1 revenue of $6.96 billion and a net profit …

Lombard Odier Asset Management USA Corp Takes Position in Ermenegildo Zegna N.V. $ZGN

Gildan Activewear, Inc. $GIL Shares Bought by Cumberland Partners Ltd

Cumberland Partners Ltd significantly increased its stake in Gildan Activewear, Inc. (NYSE:GIL) in Q1 2026, boosting its holdings by 1,307.7% to 325,168 shares, valued at approximately $18.1 million. This comes as Gildan Activewear reported strong quarterly results, with EPS of $0.43 and revenue of …

Cannell & Spears LLC Boosts Stock Holdings in Gildan Activewear, Inc. $GIL

Cannell & Spears LLC increased its stake in Gildan Activewear, Inc. (NYSE:GIL) by 4.7% in the first quarter, now owning 1,241,531 shares valued at $69,027,000. Other institutional investors have also adjusted their holdings in the textile maker. The article further details Gildan Activewear's stock …

Gilead Sciences Inc. stock underperforms Friday when compared to competitors

Gilead Sciences Inc. (GILD) saw its stock slide by 1.18% on Friday, closing at $129.31 despite a generally favorable day for the stock market, where the S&P 500 Index and Dow Jones Industrial Average both rose. This performance broke a two-day winning streak for …

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving -1.18% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.05% for the day. Elsewhere, the Dow gained 0.46%, while the tech-heavy Nasdaq …

Gildan Activewear Inc. stock rises Friday, outperforms market

Gildan Activewear Inc. (GIL) saw its stock rise by 0.82% to C$70.48 on Friday, outperforming the S&P/TSX Composite Index which gained 0.50%. Despite this gain, the company's shares closed 29.8% below its 52-week high of C$100.44 reached in February.

BofA Securities Maintains Ermenegildo Zegna NV(ZGN.US) With Hold Rating, Raises Target Price to $14.4

BofA Securities has reiterated its Hold rating for Ermenegildo Zegna NV (ZGN.US) while simultaneously increasing its price target for the stock to $14.4. This adjustment reflects the firm's ongoing assessment of the luxury fashion company's market position and future prospects.

Enterprise value to revenue forward of Gildan Activewear Inc. – MUN:VGA

This article provides an "Enterprise value to revenue forward" metric for Gildan Activewear Inc. (MUN:VGA), listed on the Munich Stock Exchange. It indicates that the market was closed with no trades at the time of publication. The content also lists various financial and community …

J&J, Gilead among recipients of EU drug nods this week (JNJ)

The European Medicines Agency's expert panel endorsed 12 new medicines and eight label expansions this week, impacting major pharmaceutical companies. Johnson & Johnson and Gilead are among the U.S. drugmakers receiving positive recommendations for their products. These approvals could allow J&J to enter the …

M.D. Sass LLC Makes New Investment in Gildan Activewear, Inc. $GIL

M.D. Sass LLC has reportedly taken a new position in Gildan Activewear, Inc. (NYSE:GIL), acquiring 396,504 shares valued at approximately $22.1 million, which now represents 1.7% of M.D. Sass's portfolio. This investment comes amidst positive Wall Street sentiment, with 13 Buy ratings and 4 …

GILD|Gilead Sciences Inc|Kurs:138.360|Änderung %:+0.220

EU panel recommends Trodelvy-Keytruda after 35% lower progression-or-death risk

Gilead Sciences announced that the European Medicines Agency's CHMP has recommended marketing authorization for Trodelvy in combination with Keytruda for first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. This recommendation is based on the ASCENT-04/KEYNOTE-D19 study, which showed a 35% reduced risk of disease …

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union – – ASCENT-04/KEYNOTE-D19 Demonstrated a Highly Statistically Significant and Clinically Meaningful Reduction in the Risk of Disease Progression or Death – FOSTER CITY, Calif., …

Walleye Capital LLC Acquires New Position in Gildan Activewear, Inc. $GIL

Walleye Capital LLC has acquired a new position in Gildan Activewear, purchasing 24,934 shares valued at approximately $1.39 million during the first quarter. Institutional investors collectively own 82.83% of Gildan's stock, with several firms increasing their stakes, including Icon Advisers, Levin Capital Strategies, PNC …

Swiss National Bank Increases Position in Gildan Activewear, Inc. $GIL

The Swiss National Bank significantly increased its stake in Gildan Activewear (NYSE:GIL) by 27% in Q1, now holding 592,125 shares valued at $32.9 million. Analysts maintain a generally bullish outlook on GIL, with 13 Buy ratings, 4 Hold ratings, and a consensus price target …

Ermenegildo Zegna: Improving Momentum, But Valuation, Brand Complexity Limit Upside (ZGN)

Ermenegildo Zegna N.V. (ZGN) H1 2026 Sales/ Trading Statement Call - Slideshow (NYSE:ZGN)

This article announces that Ermenegildo Zegna N.V. has published a slide deck in conjunction with its H1 2026 Sales/Trading Statement Call. The content was provided by SA Transcripts, Seeking Alpha's team responsible for earnings call transcripts.

Ermenegildo Zegna Q2 Earnings Call Highlights

Key Points Interested in Ermenegildo Zegna N.V.? Here are five stocks we like better. Ermenegildo Zegna reported second-quarter 2026 revenue of EUR 517 million, up 11% organically, with management saying the quarter showed sequential acceleration and broad-based strength in direct-to-consumer sales. The company's retail-first …